Retour au classement

GE HealthCare Technologies Inc. (GEHC)

Juste valeur
HealthcareMedical DevicesUnited States

Fondamental

54

Prix

$64.32

Capitalisation boursière

$30.20B

Partie 1 · Ce que vaut l'entreprise

Vue d'ensemble

GE HealthCare makes the diagnostic imaging equipment hospitals use to see inside the body — MRI, CT, X-ray, ultrasound and PET scanners — plus the contrast agents and radioactive tracers that make those scans clearer and the monitors and ventilators used to track patients at the bedside. Spun off from General Electric in 2023, it sells mainly to hospitals and health systems worldwide, competing in a market shared by a small number of large, similarly capable equipment makers.

Comment l'entreprise gagne de l'argent

Revenue mixes large, lumpy equipment sales — an MRI or CT scanner can cost hospitals millions of dollars — with recurring, higher-margin revenue from service contracts, software and the imaging agents and tracers that must be repurchased for every scan. Equipment sales depend on hospital capital budgets and can be deferred, while service and consumable revenue is stickier once a machine is installed. AI-enabled software features are an increasing share of what GE HealthCare sells alongside the hardware.

Chiffre d'affaires par segment

Advanced Imaging Solutions70.78%

MRI, CT, X-ray, ultrasound and PET imaging equipment plus the advanced visualization software used to interpret the images.

Patient Care Solutions14.96%

Patient monitors, ventilators, anesthesia delivery and other equipment used to track and support patients at the bedside.

Pharmaceutical Diagnostics14.06%

Contrast agents and radioactive tracers injected into patients to make imaging scans clearer and diagnoses more precise.

Other0.19%

Financial services supporting equipment leasing and purchases, a small residual outside the three main product lines.

Avantage concurrentiel

Coûts de changement · Étroit

Hospitals that buy a GE HealthCare scanner also commit to years of service contracts, staff training and integration with existing IT systems, making a switch to a rival brand costly and disruptive. That lock-in supports recurring service and consumables revenue, but Siemens Healthineers and Philips offer comparably capable equipment, so hospitals do switch brands at each new purchase cycle.

Ce qui stimule la demande

Modérément cyclique

Healthcare spending overall is fairly defensive, but big-ticket imaging equipment purchases are capital decisions hospitals can postpone when budgets tighten or interest rates rise, unlike the recurring consumables and service revenue tied to machines already installed. Aging populations and rising diagnostic scan volumes support long-term demand, while hospital reimbursement and capital-spending cycles create shorter-term swings.

Principaux risques

  • Hospital capital spending cycles — Large equipment purchases can be postponed when hospital budgets tighten or financing costs rise, creating lumpy order flow that does not track the steadier growth of the underlying diagnostics market.
  • Spin-off leverage — GE HealthCare took on new debt as part of its 2023 separation from General Electric; that leverage leaves less room to absorb a downturn or fund acquisitions than a business with a cleaner balance sheet.
  • Competition from Siemens Healthineers and Philips — Both rivals sell comparably capable imaging and patient-monitoring equipment, and hospitals routinely evaluate all major vendors at each replacement cycle, limiting GE HealthCare's pricing power.
  • Regulatory and product approval risk — Medical devices, imaging agents and radiopharmaceuticals require regulatory clearance in every market sold; delays, recalls or stricter rules can push back launches or force costly remediation.

Concentration des clients

GE HealthCare sells to thousands of hospitals and health systems across more than 100 countries, so no single customer accounts for a material share of revenue.

Les arguments en faveur

Buyers argue that GE HealthCare's installed base of imaging equipment across thousands of hospitals generates durable, high-margin recurring service and consumables revenue, and that aging populations and expanding diagnostic and AI-enabled software use support years of underlying growth.

Les arguments contre

Sellers fear that big-ticket equipment sales are exposed to hospital capital-spending cuts, that debt taken on at the 2023 spin-off limits financial flexibility, and that Siemens Healthineers and Philips can match GE HealthCare's technology closely enough to keep pricing power in check.

Written by the editors, published on 18 août 2026

Direct competitors

Who this company fights with for the same customers

Generated on 18 septembre 2026 with claude-haiku-4-5 — shared with all users

Siemens Healthineers AGSHL

GE HealthCare's 10-K names it a primary global competitor: the two sell the same CT, MRI, X-ray, molecular imaging and ultrasound systems, plus service contracts, to the same hospitals and imaging centres worldwide.

Koninklijke Philips N.V.PHIA

Named in the 10-K as a primary competitor: Philips bids against GE HealthCare on imaging systems, ultrasound and above all on hospital patient monitoring, the heart of GE's Patient Care Solutions segment.

Canon Inc. (キヤノン株式会社)7751

Through its Canon Medical Systems subsidiary, named in GE HealthCare's 10-K, it sells competing CT, MRI, X-ray and ultrasound systems to the same hospital buyers, pushing hard on mid-range price-performance.

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (深圳迈瑞生物医疗电子股份有限公司)300760

Named in the 10-K, Mindray competes directly for the same patient-monitoring, anaesthesia and ultrasound budgets, and has become the volume alternative in China and other emerging markets.

Shanghai United Imaging Healthcare Co., Ltd. (上海联影医疗科技股份有限公司)688271

Also named in the 10-K, it sells high-specification CT, MRI and PET systems at lower prices, taking imaging tenders from GE HealthCare first in China and increasingly abroad.

Bayer AGBAYN

In the Pharmaceutical Diagnostics segment, the 10-K names Bayer as a direct rival: both supply the contrast media injected during CT and MRI scans, sold to the same hospitals and radiology chains.

Bilan & Liquidités

Chiffre d'affaires

$20.98B

12 derniers mois (au 31/03/2026)

Résultat net

$1.91B

12 derniers mois (au 31/03/2026)

Flux de trésorerie libre

$1.50B

Capitaux propres totaux

$10.38B

Passif total

$26.31B

Ratio de liquidité général

1.22

Couverture des intérêts

-

Dette/EBITDA

2.94

Bénéfice par action

Chiffre d'affaires & Résultat net

Flux de trésorerie libre

Décomposition du résultat

État historique

Marges dans le temps

La dette dans le temps

Le poids de la dette

Grille de la croissance

Croissance — Chiffre d'affaires

Estimation de la juste valeur

Cas généralJustement valorisé

Juste valeur

$63.46

Prix actuel

$64.32

Marge de sécurité

-1.4%

Fourchette de juste valeur

$47.93 - $78.98

Écart entre les méthodes de valorisation utilisées, pas un intervalle de confiance calibré statistiquement.

Méthodes d'estimation

Objectif de cours des analystes:$83.05
Flux de trésorerie actualisés (DCF):$60.39
Multiple de résultat (P/E):$54.48
Formule de croissance de Graham:$32.46
Valeur de la capacité bénéficiaire (EPV):$52.21
P/B justifié:$66.33
Actualisation des dividendes (Gordon):$2.85
P/FFO, les fonds provenant de l'exploitation:Données insuffisantes pour le calculer
Bénéfices de milieu de cycle:$121.64
Multiple sur le chiffre d'affaires:$184.56
Consensus des analystes:Acheter (19B / 9H / 0S)
Dernière surprise sur les résultats:+7.03%

Indicateurs de valorisation

Ratio P/E

15.68

ROE

20.1%

Ratio P/B

2.79

P/FCF

19.58

Marge brute

39.1%

ROIC

7.3%

Radar de rentabilité

Création de valeur (avantage concurrentiel)

ROIC

7.3%

WACC

6.7%

ROIC − WACC

+0.6 pp

Le ROIC est à peu près aligné sur le coût du capital — l'entreprise couvre à peine son coût du capital.

Critères d'analyse fondamentale

Réussi (15)

  • ROIC 7.3%
  • Gross Margin 39.1%
  • P/FCF 19.58
  • P/B Ratio 2.79
  • Debt/Equity ratio
  • Operating Margin 12.6%
  • Positive Free Cash Flow
  • Current Ratio
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 18.9%
  • Analyst Consensus 68% Buy
  • Earnings Quality (OCF/NI) 1.06
  • Share Dilution -0.3%
  • Piotroski F-Score 5/9

Échoué (10)

  • EPS shows upward trend
  • EPS CAGR -2.08%
  • Price CAGR 3.15%
  • CapEx intensity
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Fairly valued)
  • Revenue Growth 5Y 3.7%
  • Earnings Surprise avg 0.1%
  • Net Margin Trend 9.1% vs 11.0%

Indisponible (3)

  • Dividend Payout NaN%
  • Interest Coverage
  • PEG Ratio (need PE > 0 and growth > 0)

Score F de Piotroski

5/9

Signaux mixtes : certains domaines nécessitent attention

score
criteria

Qualité des bénéfices

1.06

Qualité élevée : bénéfices soutenus par la trésorerie

Dilution du capital

-0.3%

Rachat d'actions. Favorable aux actionnaires

Participations institutionnelles

Gouvernance

Équipe dirigeante

NomTitreÂge
Mr. Peter J. ArduiniPresident, CEO & Director60
Dr. Taha Kass-Hout M.D., M.S.Chief Science & Technology Officer53
Mr. Frank R. Jimenez Esq.General Counsel & Corporate Secretary60
Ms. Jeannette BankesPresident & CEO of Patient Care Solutions54

Risque d'audit

1

Risque du conseil

5

Risque de rémunération

5

Risque droits des actionnaires

5

Partie 2 · Le prix et le moment d'entrer

Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.

Documents

  • Rapport annuel (10-K)

    Un aperçu annuel de l'activité, des résultats financiers et des risques de l'entreprise.

    Déposé le 2026-02-04

    Voir le document
  • Rapport trimestriel (10-Q)

    Une mise à jour de la performance financière des trois derniers mois.

    Déposé le 2026-07-29

    Voir le document
  • Rapport d'événement important (8-K)

    Un avis concernant un événement important, comme un changement de direction ou une annonce majeure.

    Déposé le 2026-09-22

    Voir le document

via SEC EDGAR

Historique des résultats

via SEC EDGAR

Latest News

Recent headlines for GEHC, sourced from Markets Gazette.

  • 28d agoNEGATIVE
    These stocks in the red-hot healthcare sector have gotten too crowded to own

    Analysts are recommending an options strategy to bet against GE HealthCare, citing that the stock has become too crowded with bullish positions. This suggests a potential for a sharp reversal if sentiment shifts or if the company fails to meet elevated expectations. The crowded nature of the trade implies that many investors have already piled into the healthcare stock, increasing the risk of a significant sell-off. For investors, this signals a potential downside risk and a need for caution in the short term.

via Markets Gazette